Public Companies
Wellbeing Digital Announces Resignation of Directors
Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation…
Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that James Henning and Steven Inglefield have stepped down as directors of the Company
“James has served on the Wellbeing board of directors since the Company’s inception. Overtime he has made many contributions to the success and growth of the Company, drawing on a wealth of experience gained over a long and successful business career.”
Najla Guthrie, CEO of Wellbeing
“Steven has served as a Director of the Company as well as its Chief Operating Officer since the purchase of IRP Health Ltd. (“IRP”) and made considerable contributions during his tenure. With the Company’s decision to divest IRP Health Ltd. (“IRP”), Steven leaves to focus on IRP’s expanding growth.”
Najla Guthrie, CEO of Wellbeing
“On behalf of the board of directors, the management team and our shareholders, I thank James and Steven for their contributions and wish them the best in their future endeavours,” added Najla.
About Wellbeing Digital Sciences
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
-
Psychedelics1 week agoExploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics1 week agoAll About the New Ketamine Trial at the University of Otago
-
Psychedelics1 week agoCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Law & Regulation1 week ago
Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center
-
Law & Regulation1 week agoSynaptogenix increases psilocybin stake with PsygaBio
-
Psychedelics7 days agoThe EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
-
Psychedelics1 week ago
Exploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics7 days ago
The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
